Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)
18,004 patients profiled with a targeted clinical panel - the largest cohort in the Genomic Data Commons, with no informative vital status, no race data, and no treatment records.
Can it answer your research question?
0 of 6 supportedOverall survival
Not supportedVital status is recorded for every case and informative for none.API
Progression or recurrence
Not supportedprogression_or_recurrenceis informative for no case in the harmonized records.APITreatment response
Not supportedtreatment_outcomeis populated for no case in the harmonized records.APIWhich drug was given
Not supportedtherapeutic_agentsis recorded for no case in the harmonized records.APIStage-adjusted modelling
Not supportedajcc_pathologic_stageis informative for no case in the harmonized records.APIAnalysis by race or ethnicity
Not supportedRace is informative for no case in the harmonized records.API
At a glance
Every percentage is the repository’s own record of what is filled inSubjectCALC
As filed by the repository
Who is in the cohortAPI
- Sex10,197 female · 7,798 male · 9 unknown
- Race18,004 not reported
- Ethnicity18,004 not reported
- Vital status18,004 not reported
Age at diagnosis
How complete all 29 clinical fields are - 5 informative for at least 80% of cases
Outcome
Follow-up
Treatment
Diagnosis
Demographics
Access
Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required
- Open components
- 84 open-access files
- Controlled components
- 54,012 controlled-access files
- Typical turnaround
- days to a few weeks after signing official approval
- License
- NIH Genomic Data Sharing Policy terms
- Citation requirement
- Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.
What it is good for
Written and checked by a reviewer, not generated from metadata.
1. What are the mutation frequencies and co-occurrence patterns of clinically targeted genes in a large real-world oncology population?
Needs approved accessn ≈ 18,004HUMAN18,004 patients profiled on a clinical panel give tight confidence intervals on alteration frequencies, including for alterations too rare to study in a thousand-patient research cohort. Frequency and co-occurrence need only the variant calls and the tumor type, both of which are present.
Statistical note: Panel composition bounds what can be counted: absence of a gene from the panel is not absence of alteration. Report frequencies only for genes on the panel and state the panel version.
NeedsTargeted DNA paneldiagnoses.primary_diagnosis2. How does the mutational landscape of clinically sequenced patients differ from that of research cohorts such as TCGA?
Needs another datasetn ≈ 18,004HUMANClinical sequencing populations are enriched for advanced and pretreated disease relative to the largely treatment-naive primary tumors in research cohorts. With 18,004 cases the comparison is well powered, and the discrepancy is itself a caution about generalising research-cohort findings to clinical practice.
Statistical note: Restrict the comparison to genes present on both assays and to matched tumor types; differences in assay sensitivity and tumor purity confound naive comparisons.
NeedsTargeted DNA panel3. How common are actionable alterations across tumor types in routine practice?
Needs approved accessn ≈ 18,004HUMANScale plus a clinically-deployed panel makes this the right cohort for estimating what fraction of patients would be eligible for a given targeted therapy, a question that research cohorts systematically answer wrong.
Statistical note: Eligibility estimates apply to the population that received clinical sequencing, which is not the whole cancer population.
NeedsTargeted DNA panel
What it cannot tell you
Written by a reviewer against the source, not inferred from what is missing.
Vital status is populated for 100% of the 18,004 cases and informative for 0%: every value is "not reported". Progression or recurrence and last known disease status show the same pattern - fully populated, entirely uninformative. No outcome endpoint of any kind can be derived.
Affects: Survival analysis; Prognostic modeling; Any outcome-anchored question
Mitigation: None. Choose a different cohort for any outcome question.
Every treatment field is empty for every case: prior treatment, treatment type, therapeutic agents, treatment outcome and line of therapy are all at 0% coverage.
Affects: Treatment-response analysis; Resistance mechanisms; Line-of-therapy questions
Mitigation: None. Note that this is a clinically sequenced and therefore largely pretreated population, so alteration frequencies reflect an unrecorded treatment history.
Race is recorded as "not reported" for all 18,004 patients. The largest cohort the Genomic Data Commons holds contributes nothing to any question about how cancer genomics differs across populations.
Affects: Disparities research; Ancestry-stratified analysis
Mitigation: Germline-based ancestry inference is not appropriate here; the assay is a tumor-only targeted panel and the consent scope does not contemplate it.
Patients enter this cohort by being referred for clinical tumor sequencing, which selects for advanced disease, access to specialist care and insurance coverage.
Affects: Population frequency estimates; Generalization to all patients
Mitigation: Describe results as applying to clinically sequenced patients, not to all patients.
54,012 of 54,096 files are controlled access; only 84 files are open.
Affects: Everything except catalog browsing
Mitigation: Confirm from this page that your question survives the annotation gaps before starting an access request, because scoping with open files is not possible at this ratio.
Not appropriate for
- Any survival, prognostic or outcome analysis. - Vital status is uninformative for all 18,004 cases.HUMAN
- Any treatment or resistance analysis. - All treatment fields are empty.HUMAN
- Any analysis of racial or ethnic differences. - Race is "not reported" for every patient in the cohort.HUMAN
- Estimating population-level mutation prevalence. - The cohort is ascertained by clinical referral for sequencing and carries no sampling frame or denominator.HUMAN
Who has used it
Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.
What articles did with it
- Mentioned the dataset0
- Accession found in text6
- Declared using it6
- Analyzed the data6
Against comparable datasets
- Analyzed it6
- Expected~45
METHODS:"phs001179"), so every dataset in the corpus is counted the same way and the numbers can be compared. The 7 articles listed below were retrieved and graded one at a time, and an article counts as having analyzed the data wherever the accession sits in the analysis - methods, results, tables, figures or supplement - under any of this dataset’s accessions. Read the list as the evidence about these articles, and the count as the number that is comparable across datasets.- 6 article(s) reference this dataset's accession in a methods section, against 44.8 predicted for datasets of comparable size, age, modality breadth and access tier (reuse gap index -2.71 on a log2 scale, 3rd percentile of the assessed corpus).
Possible original publication, unverified
Articles that analyzed the data
Community examples
Share your exampleAnalyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.
Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?
Audit whether this dataset can answer your question
- A GDC project identifier
- Network access to api.gdc.cancer.gov
- Per-field coverage table separating populated from informative values
- Assay coverage as a percentage of the cohort
- A yes/no verdict for six common analysis classes
- A chart contrasting populated with informative coverage, field by field
Steps
- Fetch project summary and per-assay case counts
- Request facet counts for the clinical fields that gate common analyses
- Separate absent fields from fields populated with non-answers
- Flag one-to-many fields where per-case percentages cannot be inferred
- Retrieve case-level fields and test whether a survival endpoint is derivable
- Print a verdict for each analysis class
Start here
Starter code generated from this record’s own identifiers, then the access steps.
Get the data in code
GDC: list open files and download thempython
import json, requests
PROJECT = "FM-AD"
filters = {"op": "and", "content": [
{"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
{"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
"fields": "file_id,file_name,data_category,data_type,file_size",
"size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")
# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txtGDC: clinical table for every casepython
import json, requests
filters = {"op": "in", "content": {"field": "project.project_id", "value": ["FM-AD"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
"fields": ",".join([
"submitter_id", "demographic.vital_status", "demographic.days_to_death",
"diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
"diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("FM-AD_clinical.tsv", "w").write(tsv)This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-fm-ad.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'Access steps
- Check your question against the annotation gaps aboveFor people
Almost all files are controlled, so scoping after approval is expensive. The three blocking limitations on this page rule out most reasons people arrive at a cohort of this size.
- Submit a dbGaP data access request if the question survivesFor peoplehttps://gdc.cancer.gov/access-data/obtaining-access-controlled-data
- Query the project from code, with no credentialsFor agents
The file index is public even where files are not, so an agent can size the cohort before anyone requests access.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -s 'https://api.gdc.cancer.gov/files' --get \ --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["FM-AD"]}}' \ --data-urlencode 'fields=file_id,file_name,data_type' \ --data-urlencode 'size=10000' --data-urlencode 'format=TSV' - Pass the token when the agent needs controlled filesFor agents
Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
Provenance
All of it, and more, is in this record’s JSON.
Versions and verification
- Released
- 1 Jan 2017
- Metadata retrieved
- 18 Sept 2026
- Review status
- Project-curatedCD2S project curation on 18 Sept 2026
- Data generation funding
- Funded data generation
Funding
Funded reuse of these data
- T32CA009172Physician Scientist Training in Cancer ResearchJennifer R Brown, James A. DeCaprioAPI
- R01CA227388Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsEliezer M Van AllenAPI
- R01CA203636Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentMizuki NishinoAPI
- K08CA234458Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyDavid LiuAPI
- T32CA009666T32 Research Training in Academic Medical OncologyMichael Davies, Courtney DiNardoAPI
Funded infrastructure or harmonization
- U01CA209414The Boston Lung Cancer Survival CohortDavid C ChristianiAPI
- P30CA008748Antitumor AssessmentElisa de Stanchina, FRANCESCA M GANYAPI
- U01CA247760Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing DataKen ChenAPI